Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter, Prospective Phase 2 Study to Evaluate the Duration of Treatment With Cabozantinib Among Patients With Metastatic or Locally Advanced Renal Cell Carcinoma on Hemodialysis (HD).

NCT05241561 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT05241561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05241561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter, Prospective Phase 2 Study to Evaluate the Duration of Treatment With Cabozantinib Among Patients With Metastatic or Locally Advanced Renal Cell Carcinoma on Hemodialysis (HD).
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2022
Completion date
March 31, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of kidney